Unmet Medical Need:  Transcranial magnetic stimulation (TMS) is an FDA-approved therapy for treatment-resistant depression (TRD). While some what effective (~50%), TMS is limited at present by a “one size fits all” approach to estimating the appropriate scalp location across individuals. There is a need to improve efficacy and accuracy associated with TMS.

Envisioned Healthcare Product: This project takes advantage of recent advances in brain imaging (MRI) to precisely localize the dorsolateral prefrontal cortex (DLPFC) location for each individual prior to stimulation in order to increase targeting precision. This personalized approach increases effectiveness and reduces cost versus current TMS practice.

Stage of Development:  Proof of Concept

Collaborative Research Team:  Daniel C. Javitt, MD, PhD and Paul Sajda, PhD

Funding Cycle: 2020-2021